The clinical effect Adefovir dipivoxil in Lamivudine resistant HBeAg positive chronic hepatitis B patients

Objective To evaluate the clinical effect of Adefovir dipivoxil (ADV) therapy in Lamivudine (LAM) resistant HBeAg-positive chronic hepatitis B (CHB) patients.Methods Seventy-five Lamivudine resistant HBeAg-positive CHB patients were divided into two groups: ADV group or ADV combined with LAM group.The clinical data including the levels of serum HBVDNA, HBV markers and ALT measurements were collected at baseline, week 12, week 24 and week 48.Results At the end of treatment patients with undetected HBVDNA level (< 3log10 copy/ml) and HBeAg-negative’ s were 62.5% and 31.3%, 29.6% and 11.1% (P < 0.01) in combined therapy and ADV monotherapy group, respec-tively.The HBeAg seroconversion and the ALT normalization rates were 16.7% and 91.7%, and 7.4% and 88.9% (P > 0.05) in the combined therapy and ADV monotherapy, respectively.No renal toxic effects were observed at the end of study.Conclusion Adefovir dipivoxil and lamivudine combination therapy is effective and safe for Lamivudine resistant CHB patients.